Get access

Serial echocardiography in very preterm infants: a pilot randomized trial

Authors


  • Trial registration: clinical trials.gov–NCT01031316.

Correspondence

Sara DeMauro, The Children's Hospital of Philadelphia, 2nd Floor Main Building, Division of Neonatology, 34th Street and Civic Center Boulevard, Philadelphia, PA 19104, USA.

Tel: +1 215-590-1653

Fax: +1 215-590-3051

Email: demauro@email.chop.edu

Abstract

Aim

To determine whether routine echocardiography increases diagnosis and treatment for patent ductus arteriosus (PDA) and whether randomized nondisclosure is a feasible strategy for studying PDA management.

Methods

Two–centre, pilot randomized, controlled trial. 88 infants with birth weights ≤1250 grams and gestational ages ≤30 weeks were randomized to disclosure or nondisclosure of serial echocardiogram findings. Echocardiograms were performed at 3–5 and 7–10 days of life. The primary outcome was time to regain birth weight.

Results

100% of echocardiograms in the disclosure group were disclosed; 16% (echocardiogram #1) and 29% (echocardiogram #2) were disclosed in the nondisclosure group. There was a statistically nonsignificant decrease in drug therapy for PDA in the nondisclosure group (adjusted odds ratio [AOR] 0.56, 95% confidence interval [CI] 0.24–1.34). There was no difference in time to regain birth weight or in other important neonatal outcomes. However, infants in the nondisclosure group were more likely to demonstrate appropriate weight loss and then regain birth weight within 7–14 days (AOR 2.64, 95% CI 1.08–6.44).

Conclusion

Randomized nondisclosure of echocardiograms is a feasible strategy for evaluation of approaches to PDA management in very preterm infants. Avoidance of routine echocardiography may reduce drug therapy for PDA without adverse clinical effects.

Get access to the full text of this article

Ancillary